Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.

ABSTRACT

ConditionCOVID-19;Immunocompromised Host

Primary outcome:Neutralizing antibody activity;Neutralizing antibody activity;Neutralizing antibody activity;Neutralizing antibody activity;Neutralizing antibody activity;Neutralizing antibody activity;Neutralizing antibody activity;Neutralizing antibody activity

Criteria
Inclusion Criteria

- Adults (18 years-old or more)

- Patient who received the first administration of Evusheld at 300 mg for less than 4
months and should receive a second dose, according to French recommendations OR
Patient scheduled to receive or having received less than a month ago an injection of
anti-SARS-CoV-2 monoclonal antibodies, as pre-exposure prophylaxis at 600 mg,
according to the French SARS-CoV-2 RT recommendations

- qPCR negative at baseline

- SARS-CoV-2 RT-qPCR Negative at inclusion

- Patients who remain seronegative after a complete COVID-19 vaccination schedule

- Immunocompromised patients

Hemopathy chronic lymphoid leukemia, non hodgkin's lymphoma, HSCT Transplant recipient
kidney, liver, lungs Patients receiving anti CD20 or others immunosuppressor

- Life expectancy > 3 months

- Social security affiliation

- Lack of a legal protection measure

- Signed informed consent

Exclusion Criteria

- Participation to another clinical study

- State medical aid

- Ongoing or scheduled plasmapheresis or immunoadsorption

- Pregnant / lactating woman

- Patient whose isolation period is underway following contact with a confirmed case of
SARS-CoV2 infection

- Hypersensitivity to one of the active substances or to one of the excipients